
Global Human iPSCs Market Outlook and Growth Opportunities 2025
Description
Summary
According to APO Research, the global Human iPSCs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Human iPSCs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Human iPSCs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Human iPSCs market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Human iPSCs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Human iPSCs market include Sumitomo Dainippon Pharma, ReproCELL, Pluricell Biotech, Ncardia, Fujifilm Holding Corporation (CDI), Fate Therapeutics, Inc, Cell Inspire Biotechnology and Astellas Pharma Inc, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Human iPSCs, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Human iPSCs, also provides the value of main regions and countries. Of the upcoming market potential for Human iPSCs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Human iPSCs revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Human iPSCs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Human iPSCs company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Human iPSCs Segment by Company
Sumitomo Dainippon Pharma
ReproCELL
Pluricell Biotech
Ncardia
Fujifilm Holding Corporation (CDI)
Fate Therapeutics, Inc
Cell Inspire Biotechnology
Astellas Pharma Inc
Human iPSCs Segment by Type
Skin
Blood Cells
Human iPSCs Segment by Application
Regenerative Medicine
Drug Development and Discovery
Academic Research
Toxicity Screening
Others
Human iPSCs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Human iPSCs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Human iPSCs key companies, revenue, market share, and recent developments.
3. To split the Human iPSCs breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Human iPSCs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Human iPSCs significant trends, drivers, influence factors in global and regions.
6. To analyze Human iPSCs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human iPSCs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human iPSCs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human iPSCs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human iPSCs industry.
Chapter 3: Detailed analysis of Human iPSCs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Human iPSCs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Human iPSCs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
According to APO Research, the global Human iPSCs market is projected to grow from US$ million in 2025 to US$ million by 2031, at a compound annual growth rate (CAGR) of % during the forecast period.
The North American market for Human iPSCs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % from 2025 through 2031.
The Asia-Pacific market for Human iPSCs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
In China, the Human iPSCs market is expected to rise from $ million to $ million by 2031, at a CAGR of I% from 2025 through 2031.
The Europe market for Human iPSCs is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Major global companies in the Human iPSCs market include Sumitomo Dainippon Pharma, ReproCELL, Pluricell Biotech, Ncardia, Fujifilm Holding Corporation (CDI), Fate Therapeutics, Inc, Cell Inspire Biotechnology and Astellas Pharma Inc, etc. In 2024, the top three vendors accounted for approximately % of the market revenue.
This report presents an overview of global market for Human iPSCs, revenue and gross margin. Analyses of the global market trends, with historic market revenue for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.
This report researches the key producers of Human iPSCs, also provides the value of main regions and countries. Of the upcoming market potential for Human iPSCs, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Human iPSCs revenue, market share and industry ranking of main companies, data from 2020 to 2025. Identification of the major stakeholders in the global Human iPSCs market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
All companies have demonstrated varying levels of sales growth and profitability over the past six years, while some companies have experienced consistent growth, others have shown fluctuations in performance. The overall trend suggests a positive outlook for the global Human iPSCs company landscape, with companies adapting to market dynamics and maintaining profitability amidst changing conditions.
Human iPSCs Segment by Company
Sumitomo Dainippon Pharma
ReproCELL
Pluricell Biotech
Ncardia
Fujifilm Holding Corporation (CDI)
Fate Therapeutics, Inc
Cell Inspire Biotechnology
Astellas Pharma Inc
Human iPSCs Segment by Type
Skin
Blood Cells
Human iPSCs Segment by Application
Regenerative Medicine
Drug Development and Discovery
Academic Research
Toxicity Screening
Others
Human iPSCs Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Study Objectives
1. To analyze and research the global Human iPSCs status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.
2. To present the Human iPSCs key companies, revenue, market share, and recent developments.
3. To split the Human iPSCs breakdown data by regions, type, companies, and application.
4. To analyze the global and key regions Human iPSCs market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify Human iPSCs significant trends, drivers, influence factors in global and regions.
6. To analyze Human iPSCs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Human iPSCs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Human iPSCs and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Human iPSCs.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size.
Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Human iPSCs industry.
Chapter 3: Detailed analysis of Human iPSCs company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales value of Human iPSCs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.
Chapter 7: Sales value of Human iPSCs in country level. It provides sigmate data by type, and by application for each country/region.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 9: Concluding Insights.
Table of Contents
195 Pages
- 1 Market Overview
- 1.1 Product Definition
- 1.2 Global Human iPSCs Market Size, 2020 VS 2024 VS 2031
- 1.3 Global Human iPSCs Market Size (2020-2031)
- 1.4 Assumptions and Limitations
- 1.5 Study Goals and Objectives
- 2 Human iPSCs Market Dynamics
- 2.1 Human iPSCs Industry Trends
- 2.2 Human iPSCs Industry Drivers
- 2.3 Human iPSCs Industry Opportunities and Challenges
- 2.4 Human iPSCs Industry Restraints
- 3 Human iPSCs Market by Company
- 3.1 Global Human iPSCs Company Revenue Ranking in 2024
- 3.2 Global Human iPSCs Revenue by Company (2020-2025)
- 3.3 Global Human iPSCs Company Ranking (2023-2025)
- 3.4 Global Human iPSCs Company Manufacturing Base and Headquarters
- 3.5 Global Human iPSCs Company Product Type and Application
- 3.6 Global Human iPSCs Company Establishment Date
- 3.7 Market Competitive Analysis
- 3.7.1 Global Human iPSCs Market Concentration Ratio (CR5 and HHI)
- 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2024
- 3.7.3 2024 Human iPSCs Tier 1, Tier 2, and Tier 3 Companies
- 3.8 Mergers and Acquisitions Expansion
- 4 Human iPSCs Market by Type
- 4.1 Human iPSCs Type Introduction
- 4.1.1 Skin
- 4.1.2 Blood Cells
- 4.2 Global Human iPSCs Sales Value by Type
- 4.2.1 Global Human iPSCs Sales Value by Type (2020 VS 2024 VS 2031)
- 4.2.2 Global Human iPSCs Sales Value by Type (2020-2031)
- 4.2.3 Global Human iPSCs Sales Value Share by Type (2020-2031)
- 5 Human iPSCs Market by Application
- 5.1 Human iPSCs Application Introduction
- 5.1.1 Regenerative Medicine
- 5.1.2 Drug Development and Discovery
- 5.1.3 Academic Research
- 5.1.4 Toxicity Screening
- 5.1.5 Others
- 5.2 Global Human iPSCs Sales Value by Application
- 5.2.1 Global Human iPSCs Sales Value by Application (2020 VS 2024 VS 2031)
- 5.2.2 Global Human iPSCs Sales Value by Application (2020-2031)
- 5.2.3 Global Human iPSCs Sales Value Share by Application (2020-2031)
- 6 Human iPSCs Regional Value Analysis
- 6.1 Global Human iPSCs Sales Value by Region: 2020 VS 2024 VS 2031
- 6.2 Global Human iPSCs Sales Value by Region (2020-2031)
- 6.2.1 Global Human iPSCs Sales Value by Region: 2020-2025
- 6.2.2 Global Human iPSCs Sales Value by Region (2026-2031)
- 6.3 North America
- 6.3.1 North America Human iPSCs Sales Value (2020-2031)
- 6.3.2 North America Human iPSCs Sales Value Share by Country, 2024 VS 2031
- 6.4 Europe
- 6.4.1 Europe Human iPSCs Sales Value (2020-2031)
- 6.4.2 Europe Human iPSCs Sales Value Share by Country, 2024 VS 2031
- 6.5 Asia-Pacific
- 6.5.1 Asia-Pacific Human iPSCs Sales Value (2020-2031)
- 6.5.2 Asia-Pacific Human iPSCs Sales Value Share by Country, 2024 VS 2031
- 6.6 South America
- 6.6.1 South America Human iPSCs Sales Value (2020-2031)
- 6.6.2 South America Human iPSCs Sales Value Share by Country, 2024 VS 2031
- 6.7 Middle East & Africa
- 6.7.1 Middle East & Africa Human iPSCs Sales Value (2020-2031)
- 6.7.2 Middle East & Africa Human iPSCs Sales Value Share by Country, 2024 VS 2031
- 7 Human iPSCs Country-level Value Analysis
- 7.1 Global Human iPSCs Sales Value by Country: 2020 VS 2024 VS 2031
- 7.2 Global Human iPSCs Sales Value by Country (2020-2031)
- 7.2.1 Global Human iPSCs Sales Value by Country (2020-2025)
- 7.2.2 Global Human iPSCs Sales Value by Country (2026-2031)
- 7.3 USA
- 7.3.1 USA Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.3.2 USA Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.3.3 USA Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.4 Canada
- 7.4.1 Canada Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.4.2 Canada Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.4.3 Canada Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.5 Mexico
- 7.5.1 Mexico Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.5.2 Mexico Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.5.3 Mexico Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.6 Germany
- 7.6.1 Germany Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.6.2 Germany Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.6.3 Germany Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.7 France
- 7.7.1 France Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.7.2 France Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.7.3 France Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.8 U.K.
- 7.8.1 U.K. Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.8.2 U.K. Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.8.3 U.K. Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.9 Italy
- 7.9.1 Italy Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.9.2 Italy Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.9.3 Italy Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.10 Spain
- 7.10.1 Spain Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.10.2 Spain Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.10.3 Spain Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.11 Russia
- 7.11.1 Russia Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.11.2 Russia Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.11.3 Russia Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.12 Netherlands
- 7.12.1 Netherlands Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.12.2 Netherlands Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.12.3 Netherlands Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.13 Nordic Countries
- 7.13.1 Nordic Countries Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.13.2 Nordic Countries Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.13.3 Nordic Countries Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.14 China
- 7.14.1 China Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.14.2 China Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.14.3 China Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.15 Japan
- 7.15.1 Japan Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.15.2 Japan Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.15.3 Japan Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.16 South Korea
- 7.16.1 South Korea Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.16.2 South Korea Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.16.3 South Korea Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.17 India
- 7.17.1 India Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.17.2 India Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.17.3 India Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.18 Australia
- 7.18.1 Australia Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.18.2 Australia Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.18.3 Australia Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.19 Southeast Asia
- 7.19.1 Southeast Asia Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.19.2 Southeast Asia Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.19.3 Southeast Asia Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.20 Brazil
- 7.20.1 Brazil Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.20.2 Brazil Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.20.3 Brazil Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.21 Argentina
- 7.21.1 Argentina Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.21.2 Argentina Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.21.3 Argentina Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.22 Chile
- 7.22.1 Chile Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.22.2 Chile Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.22.3 Chile Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.23 Colombia
- 7.23.1 Colombia Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.23.2 Colombia Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.23.3 Colombia Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.24 Peru
- 7.24.1 Peru Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.24.2 Peru Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.24.3 Peru Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.25 Saudi Arabia
- 7.25.1 Saudi Arabia Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.25.2 Saudi Arabia Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.25.3 Saudi Arabia Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.26 Israel
- 7.26.1 Israel Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.26.2 Israel Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.26.3 Israel Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.27 UAE
- 7.27.1 UAE Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.27.2 UAE Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.27.3 UAE Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.28 Turkey
- 7.28.1 Turkey Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.28.2 Turkey Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.28.3 Turkey Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.29 Iran
- 7.29.1 Iran Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.29.2 Iran Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.29.3 Iran Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 7.30 Egypt
- 7.30.1 Egypt Human iPSCs Sales Value Growth Rate (2020-2031)
- 7.30.2 Egypt Human iPSCs Sales Value Share by Type, 2024 VS 2031
- 7.30.3 Egypt Human iPSCs Sales Value Share by Application, 2024 VS 2031
- 8 Company Profiles
- 8.1 Sumitomo Dainippon Pharma
- 8.1.1 Sumitomo Dainippon Pharma Comapny Information
- 8.1.2 Sumitomo Dainippon Pharma Business Overview
- 8.1.3 Sumitomo Dainippon Pharma Human iPSCs Revenue and Gross Margin (2020-2025)
- 8.1.4 Sumitomo Dainippon Pharma Human iPSCs Product Portfolio
- 8.1.5 Sumitomo Dainippon Pharma Recent Developments
- 8.2 ReproCELL
- 8.2.1 ReproCELL Comapny Information
- 8.2.2 ReproCELL Business Overview
- 8.2.3 ReproCELL Human iPSCs Revenue and Gross Margin (2020-2025)
- 8.2.4 ReproCELL Human iPSCs Product Portfolio
- 8.2.5 ReproCELL Recent Developments
- 8.3 Pluricell Biotech
- 8.3.1 Pluricell Biotech Comapny Information
- 8.3.2 Pluricell Biotech Business Overview
- 8.3.3 Pluricell Biotech Human iPSCs Revenue and Gross Margin (2020-2025)
- 8.3.4 Pluricell Biotech Human iPSCs Product Portfolio
- 8.3.5 Pluricell Biotech Recent Developments
- 8.4 Ncardia
- 8.4.1 Ncardia Comapny Information
- 8.4.2 Ncardia Business Overview
- 8.4.3 Ncardia Human iPSCs Revenue and Gross Margin (2020-2025)
- 8.4.4 Ncardia Human iPSCs Product Portfolio
- 8.4.5 Ncardia Recent Developments
- 8.5 Fujifilm Holding Corporation (CDI)
- 8.5.1 Fujifilm Holding Corporation (CDI) Comapny Information
- 8.5.2 Fujifilm Holding Corporation (CDI) Business Overview
- 8.5.3 Fujifilm Holding Corporation (CDI) Human iPSCs Revenue and Gross Margin (2020-2025)
- 8.5.4 Fujifilm Holding Corporation (CDI) Human iPSCs Product Portfolio
- 8.5.5 Fujifilm Holding Corporation (CDI) Recent Developments
- 8.6 Fate Therapeutics, Inc
- 8.6.1 Fate Therapeutics, Inc Comapny Information
- 8.6.2 Fate Therapeutics, Inc Business Overview
- 8.6.3 Fate Therapeutics, Inc Human iPSCs Revenue and Gross Margin (2020-2025)
- 8.6.4 Fate Therapeutics, Inc Human iPSCs Product Portfolio
- 8.6.5 Fate Therapeutics, Inc Recent Developments
- 8.7 Cell Inspire Biotechnology
- 8.7.1 Cell Inspire Biotechnology Comapny Information
- 8.7.2 Cell Inspire Biotechnology Business Overview
- 8.7.3 Cell Inspire Biotechnology Human iPSCs Revenue and Gross Margin (2020-2025)
- 8.7.4 Cell Inspire Biotechnology Human iPSCs Product Portfolio
- 8.7.5 Cell Inspire Biotechnology Recent Developments
- 8.8 Astellas Pharma Inc
- 8.8.1 Astellas Pharma Inc Comapny Information
- 8.8.2 Astellas Pharma Inc Business Overview
- 8.8.3 Astellas Pharma Inc Human iPSCs Revenue and Gross Margin (2020-2025)
- 8.8.4 Astellas Pharma Inc Human iPSCs Product Portfolio
- 8.8.5 Astellas Pharma Inc Recent Developments
- 9 Concluding Insights
- 10 Appendix
- 10.1 Reasons for Doing This Study
- 10.2 Research Methodology
- 10.3 Research Process
- 10.4 Authors List of This Report
- 10.5 Data Source
- 10.5.1 Secondary Sources
- 10.5.2 Primary Sources
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.